News & Events

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Cash Bonus Plan On February 12, 2026, the Board of Directors (the “ Board ”) of Orchestra BioMed Holdings, Inc. (the “ Company ”), upon the recommendation of the Compensation Committee of the Board (the “ Compensation Committee ”), approved the 2026 cash bonus plan for all executive officers (the “ Plan ”), which: · establishes annual goals with mi…

Other Events. On January 12, 2026, Orchestra BioMed Holdings, Inc. (the “Company”) issued a press release titled “Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics,” which press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Other Events. On October 27, 2025, the Company announced the first patient enrollments in the Virtue SAB in the Treatment of Coronary ISR Trial (“ Virtue Trial ”), the Company’s U.S. IDE pivotal trial comparing its highly differentiated Virtue® Sirolimus AngioInfusionTM Balloon (“ Virtue SAB ”) to the AGENT paclitaxel-coated balloon, currently the only drug-coated balloon (“ DCB ”) FDA-approved for a coronary indication. The initial cases were successfully completed by the teams at The Christ…

Entry into Material Definitive Agreement. Termination and Right of First Refusal Agreement On October 24, 2025 (the “ Effective Date ”), Orchestra BioMed, Inc. (“ Orchestra ”), a wholly owned subsidiary of Orchestra BioMed Holdings, Inc. (the “ Company ”), entered into a termination and right of first refusal agreement (the “ Termination and ROFR Agreement ”) with Terumo Medical Corporation (“ TMC ”) and Terumo Corporation (“ TC ” and, together with TMC “ Terumo ”), pursuant to which that cer…

Termination of a Material Definitive Agreement. The information required by this item with respect to the Termination and ROFR Agreement and the termination of the Distribution Agreement is included in

Unregistered Sales of Equity Securities. The information required by this item with respect to the Series A Preferred Stock is included in

Other Events. As previously announced, on July 31, 2025, the Company entered into Stock Purchase Agreements with Ligand Pharmaceuticals Incorporated (“ Ligand ”) and Covidien Group S.à.r.l. (an affiliate of Medtronic plc) (together with Ligand, the “ PIPE Investors ”), pursuant to which the Company issued and sold, and the PIPE Investors purchased, in a private placement (the “ Private Placement ”) an aggregate of 5,895,608 shares of Common Stock for aggregate cash proceeds of approximately $…

Entry into a Material Definitive Agreement. On August 1, 2025, Orchestra BioMed Holdings, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Piper Sandler & Co. and TD Securities (USA) LLC as the representatives of the several underwriters named therein (the “ Underwriters ”), relating to an underwritten public offering (the “ Offering ”) of an aggregate of 9,413,637 shares of the Company’s common stock, par value $0.0001 per share (“ Common St…

Entry into Material Definitive Agreement. Ligand Pharmaceuticals Incorporated Revenue Participation Right Purchase and Sale Agreement and Purchase of Shares On July 31, 2025, Orchestra BioMed Holdings, Inc. (the “ Company ”) entered into a revenue participation right purchase and sale agreement (the “ Revenue Purchase and Sale Agreement ”) with Ligand Pharmaceuticals Incorporated (the “ Purchaser ”). Under the terms of the Revenue Purchase and Sale Agreement, in exchange for payment of $35.0…

Creation of Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information required by this item with respect to the Loan Agreement, the Note and the LSA Amendment is included in

Unregistered Sales of Equity Securities. The information required by this item with respect to the Warrant, the Warrant Shares and the Private Placement Shares is included in

Other Information. Certain Unaudited Preliminary June 30, 2025 Financial Results Although the Company’s financial results for the quarter ended June 30, 2025 are not yet finalized, based on currently available information, the Company expects its cash, cash equivalents and short-term investments to be approximately $33.9 million as of June 30, 2025. The preliminary results set forth above are based on management’s initial review of the Company’s operations for the quarter ended June 30, 2025…

Other events. Breakthrough Device Designation for AVIM Therapy On April 22, 2025, the Company announced that it had received BDD for an implantable system to deliver AVIM therapy using conduction system pacing to reduce blood pressure in patients with preserved left ventricular systolic function (ejection fraction >50%) and uncontrolled hypertension with increased ten-year atherosclerotic cardiovascular disease risk (>20%), despite the use of anti-hypertensive medications or in patients who m…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Policy With Respect to the Payment of Taxes Upon Vesting of Restricted Stock Units for Section 16 Officers On February 19, 2025, the Compensation Committee (the “ Committee ”) of the Board of Directors (the “ Board ”) of Orchestra BioMed Holdings, Inc. (the “ Company ”) approved a policy regarding tax payments upon the vesting of restricted stock u…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of New Director On January 30, 2025, the Board of Directors (the “ Board ”) of Orchestra BioMed Holdings, Inc. (the “ Company ”) appointed Chris Cleary to serve as a Class II director, effective immediately, with a term expiring at the Company’s 2025 annual meeting of stockholders. Mr. Cleary was also appointed to serve as a member of t…